The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
=== Sevilla === 777 Partners' first investment in soccer was to purchase a minority stake in Spanish La Liga club Sevilla FC in 2018. In 2020, it elevated its share to 7.5%. 777 does not legally own shares in Sevilla as its involvement is as the owner of a group called Sevillistas Unidos S.L.. The latter organization has denounced 777 for listing Sevilla as one of "Our Portfolio Brands" on its website. Sevilla had been identified by 777 Partners as an opportunity for investment due to their focus on buying and selling players under sporting director Monchi. Their investment had been greeted with suspicion due to the club's history of being owned by local dynasties. 777 Partners' investment around Sevilla was allegedly funded in part by a loan from Oleg Boyko, a Russian businessman sanctioned by several countries for reported connections to the Russian state. In 2024, Boyko allegedly demanded 777's shares in Sevilla as collateral for his loan.
Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes (artificial lipid bilayer vesicles) coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body. The antibody modified liposomes target tissue through cell-specific antibodies with the release of drugs contained within the assimilated liposomes. Immunoliposome aims to improve drug stability, personalize treatments, and increased drug efficacy. This form of therapy has been used to target specific cells, protecting the encapsulated drugs from degradation in order to enhance their stability, to facilitate sustained drug release and hence to advance current traditional cancer treatment.
Sigma RBI produces specialized products for use in the field of cell signaling and neuroscience. Their offerings range from standard biochemical reagents to specialized research tools, including ligands for receptors and ion channels, enzyme inhibitors, phosphospecific antibodies, key signal transduction enzymes, and assay kits for cell signaling.
=== Evolution === The delicate skeletons of bats do not fossilise well; it is estimated that only 12% of bat genera that lived have been found in the fossil record. The oldest known bat fossils include Archaeonycteris praecursor and Altaynycteris aurora (55–56 million years ago), both known only from isolated teeth. The oldest complete bat skeletons are Icaronycteris gunnelli and Onychonycteris finneyi (52 million years ago), known from two skeletons discovered in Wyoming. The extinct bats Palaeochiropteryx and Hassianycteris from the Messel Pit of Germany, both of which lived 48 million years ago, are the first fossil mammals whose colouration has been discovered: both were reddish-brown. The largest known fossil bat known from a near-complete skeleton is Archaeopteropus (~33 million years ago) from Italy, which had a wingspan of about 82 to 90 centimetres (2.69 to 2.95 ft). Bats were formerly grouped in the superorder Archonta, along with the treeshrews (Scandentia), colugos (Dermoptera), and primates. Modern genetic evidence now places bats in the superorder Laurasiatheria, with its sister taxon as Ferungulata, which includes carnivorans, pangolins, odd-toed ungulates, and even-toed ungulates. One study places Chiroptera as a sister taxon to odd-toed ungulates (Perissodactyla).
Sources: en.wikipedia.org
=== Cold fusion === 208Pb(48Ca,xn)256−xNo (x=1,2,3,4) This cold fusion reaction was first studied in 1979 at Flerov Laboratory of Nuclear Reactions (FLNR). Further work in 1988 at GSI measured EC and SF branchings in 254No. In 1989, the FLNR used the reaction to measure SF decay characteristics for the two isomers of 254No. The measurement of the 2n excitation function was reported in 2001 by Yuri Oganessian at the FLNR. Patin et al. at the LBNL reported in 2002 the synthesis of 255–251No in the 1-4n exit channels and measured further decay data for these isotopes. The reaction has recently been used at Jyväskylän Yliopisto Fysiikan Laitos (JYFL) using the RITU set-up to study K-isomerism in 254No. The scientists were able to measure two K-isomers with half-lives of 275 ms and 198 s, respectively. They were assigned to 8− and 16+ K-isomeric levels. The reaction was used in 2004–5 at the FLNR to study the spectroscopy of 255–253No. The team were able to confirm an isomeric level in 253No with a half-life of 43.5 s.
Biopharmaceuticals may be produced from microbial cells (e.g., recombinant E. coli or yeast cultures), mammalian cell lines (see Cell culture) and plant cell cultures (see Plant tissue culture) and moss plants in bioreactors of various configurations, including photo-bioreactors. Important issues of concern are cost of production (low-volume, high-purity products are desirable) and microbial contamination (by bacteria, viruses, mycoplasma). Alternative platforms of production which are being tested include whole plants (plant-made pharmaceuticals).
== The economic crisis in Germany == Hitler's interest in Czechoslovakia was largely economic. Germany had the second-largest economy in the world, but German agriculture was not capable of feeding the population, and there was also a lack of many raw materials, which had to be imported. The Four-Year Plan that Hitler had launched in September 1936 to have the German economy ready for a "total war" by 1940 had seriously strained the German economy by 1937 as German government was forced to use up its foreign exchange reserves both to feed its own people and to import various raw materials to achieve the ambitious armament goals of the Four Year Plan. Though the Four Year Plan aimed at autarky, there were certain raw materials such as high-grade iron, oil, chrome, nickel, tungsten, and bauxite that Germany did not have and had to be imported. The need to import food and raw materials made Germany into Europe's second largest importer, being exceeded only by Great Britain. Moreover, hundreds of millions of Reichsmarks were spent on immense armament works such as the Reichswerke steel complex, an expensive program to develop synthetic fuel, as well as various costly chemical and metallurgical programs, all of which strained the German economy. The Great Depression was an era beset by trade wars and protectionism, which put further straining on the German export market and ability to generate foreign exchange. Moreover, the Four Year Plan with its aim of autarky led to Germany increasing its tariffs, which led other nations to do likewise in retaliation.
=== Nutrition === In nature, mice are usually herbivores, consuming a wide range of fruit or grain. However, in laboratory studies it is usually necessary to avoid biological variation and to achieve this, laboratory mice are almost always fed only commercial pelleted mouse feed. Food intake is approximately 15 g (0.53 oz) per 100 g (3.5 oz) of body weight per day; water intake is approximately 15 ml (0.53 imp fl oz; 0.51 US fl oz) per 100 g of body weight per day.
=== Cancer === In normal cells, TGF-β, acting through its signaling pathway, stops the cell cycle at the G1 stage to stop proliferation, induce differentiation, or promote apoptosis. In many cancer cells, parts of the TGF-β signaling pathway are mutated, and TGF-β no longer controls the cell. These cancer cells proliferate. The surrounding stromal cells (fibroblasts) also proliferate. Both cells increase their production of TGF-β. This TGF-β acts on the surrounding stromal cells, immune cells, endothelial and smooth-muscle cells. It causes immunosuppression and angiogenesis, which makes the cancer more invasive. TGF-β also converts effector T-cells, which normally attack cancer with an inflammatory (immune) reaction, into regulatory (suppressor) T-cells, which turn off the inflammatory reaction. Normal tissue integrity is preserved by feedback interactions between different cell types that express adhesion molecules and secrete cytokines. Disruption of these feedback mechanisms in cancer damages a tissue. When TGF-β signaling fails to control NF-κB activity in cancer cells, this has at least two potential effects: first, it enables the malignant tumor to persist in the presence of activated immune cells, and second, the cancer cell outlasts immune cells because it survives in the presence of apoptotic, and anti-inflammatory mediators. Furthermore, forkhead box protein 3 (FOXP3) as a transcription factor is an essential molecular marker of regulatory T (Treg) cells.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.